ABCB1 genotype and CSF β-amyloid in Alzheimer disease

Journal of Geriatric Psychiatry and Neurology

Volumn 24, Issue 2, 2011, Pages 63-66

  Kohen, R ^a,d   Shofer, J B ^b   Korvatska, O ^a   Petrie, E C ^a,b   Wang, L Y ^a,b   Schellenberg, G D ^a,c   Peskind, E R ^a,b   Wilkinson, C W ^a,c  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

ABCB1; Alzheimer disease; association study; dementia; MDR1; P glycoprotein

Indexed keywords

AMYLOID BETA PROTEIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1;

AGED; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; CONTROLLED STUDY; FEMALE; GENETIC CODE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

AGED; ALLELES; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; ODDS RATIO; P-GLYCOPROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 79955730740     PISSN: 08919887     EISSN: 15525708     Source Type: Journal    
DOI: 10.1177/0891988711402325     Document Type: Article

References (27)

1. Chen CJ, Chin JE, Ueda K., et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell. 1986 ; 47 (3). 381-389. (Pubitemid 17210152)
2. Fromm MF Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci. 2004 ; 25 (8). 423-429. (Pubitemid 38981558)
3. Demeule M., Regina A., Jodoin J., et al. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul Pharmacol. 2002 ; 38 (6). 339-348. (Pubitemid 36398255)
4. Lee G., Bendayan R. Functional expression and localization of Pglycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders. Pharm Res. 2004 ; 21 (8). 1313-1330. (Pubitemid 39149646)
5. Schinkel AH, Wagenaar E., Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest. 1996 ; 97 (11). 2517-2524. (Pubitemid 26187339)
6. Loscher W., Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci. 2005 ; 6 (8). 591-602. (Pubitemid 41059334)
7. Lam FC, Liu R., Lu P., et al. beta-Amyloid efflux mediated by p-glycoprotein. J Neurochem. 2001 ; 76 (4). 1121-1128.
8. Kuhnke D., Jedlitschky G., Grube M., et al. MDR1-P-Glycoprotein (ABCB1) Mediates transport of Alzheimer's amyloid-beta peptides-implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol. 2007 ; 17 (4). 347-353. (Pubitemid 47537591)
9. Cirrito JR, Deane R., Fagan AM, et al. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest. 2005 ; 115 (11). 3285-3290. (Pubitemid 41567593)
10. Vogelgesang S., Cascorbi I., Schroeder E., et al. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Pharmacogenetics. 2002 ; 12 (7). 535-541. (Pubitemid 35177083)
11. Vogelgesang S., Warzok RW, Cascorbi I., et al. The role of P-glycoprotein in cerebral amyloid angiopathy; implications for the early pathogenesis of Alzheimer's disease. Curr Alzheimer Res. 2004 ; 1 (2). 121-125.
12. Bodor M., Kelly EJ, Ho RJ Characterization of the human MDR1 gene. AAPS J. 2005 ; 7 (1). E1 - E5.
13. Leschziner GD, Andrew T., Pirmohamed M., Johnson MR ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J. 2007 ; 7 (3). 154-179. (Pubitemid 46794925)
14. Frankfort SV, Doodeman VD, Bakker R., et al. ABCB1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients. Mol Neurodegener. 2006 ; 1: 13.
15. Tsuang D., Kukull W., Sheppard L., et al. Impact of sample selection on APOE epsilon 4 allele frequency: a comparison of two Alzheimer's disease samples. J Am Geriatr Soc. 1996 ; 44 (6). 704-707.
16. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984 ; 34 (7). 939-944. (Pubitemid 14076461)
17. Folstein MF, Folstein SE, McHugh PR "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 ; 12 (3). 189-198.
18. Peskind ER, Wilkinson CW, Petrie EC, Schellenberg GD, Raskind MA. Increased CSF cortisol in AD is a function of APOE genotype. Neurology. 2001 ; 56 (8). 1094-1098. (Pubitemid 32336320)
19. Peskind ER, Li G., Shofer J., et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol. 2006 ; 63 (7). 936-939. (Pubitemid 44036292)
20. Gaunt TR, Rodriguez S., Zapata C., Day IN MIDAS: software for analysis and visualisation of interallelic disequilibrium between multiallelic markers. BMC Bioinformatics. 2006 ; 7: 227.
21. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. http://www.R-project.org. 2008. Accessed December 5, 2010.
22. Woodahl EL, Ho RJ The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab. 2004 ; 5 (1). 11-19. (Pubitemid 38279406)
23. Marzolini C., Paus E., Buclin T., Kim RB Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther. 2004 ; 75 (1). 13-33. (Pubitemid 38130115)
24. Shaw LM, Vanderstichele H., Knapik-Czajka M., et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol. 2009 ; 65 (4). 403-413.
25. Sukhai M., Piquette-Miller M. Regulation of the multidrug resistance genes by stress signals. J Pharm Pharm Sci. 2000 ; 3 (2). 268-280.
26. Su F., Ouyang N., Zhu P., et al. Psychological stress induces chemoresistance in breast cancer by upregulating mdr1. Biochem Biophys Res Commun. 2005 ; 329 (3). 888-897. (Pubitemid 40347252)
27. Spudich A., Kilic E., Xing H., et al. Inhibition of multidrug resistance transporter-1 facilitates neuroprotective therapies after focal cerebral ischemia. Nat Neurosci. 2006 ; 9 (4). 487-488.